The Fight Against HCV

In 2013, viral hepatitis was a leading cause of death worldwide. More than 90% of this burden is due to the hepatitis B virus (HBV) and hepatitis C virus (HCV).1

The 2014 World Health Assembly asked the World Health Organization (WHO) to explore how to eliminate HCV. In response, the WHO set 2030 targets for diagnosis, treatment, incidence, and mortality that would achieve the goal of eliminating HCV as a global health burden. Below are more details about the mission—as well as how we all can help make this important mission a reality.

Hepatitis C Elimination in the US

Learn what HCV experts are doing to eliminate the disease in the United States.

Explore

The treater landscape is changing

  • The paradigm is shifting toward more nonspecialist providers treating HCV2
  • Remote specialist oversight could mean more patients treated by primary care providers, with fewer specialist resources used3

Hepatitis C Elimination in the US

The HCV landscape has changed

The HCV landscape has changed.

Watch
The WHO report on eliminating hepatitis C

The WHO report on eliminating hepatitis C.

Download
MappingHepC.com

MappingHepC.com shows you where patients are located and provides characteristics of diagnosed RNA+ patients.

Explore
HCV and the opioid crisis

HCV and injection drug use.

Discover
Find a syringe exchange program near you

Find a syringe exchange program near you.

Connect
Working with the CDC to start a syringe services program

Working with the CDC to start a syringe services program.

Learn more

References:
1. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081-1088. doi:10.1016/S0140-6736(16)30579-7
2. Butt AA, Yan P, Lo Re IV, Shaikh OS, Ross DB. Trends in treatment uptake and provider specialty for hepatitis C virus (HCV) infection in the Veterans Affairs healthcare system: results from the electronically retrieved cohort of HCV-infected veterans (ERCHIVES). Clin Infect Dis. 2019;68(5):857-859. doi:10.1093/cid/ciy697
3. Thomas J, Thompson H, Wu T, et al. Direct-acting antiviral therapy in primary care following non-real time, remote specialist review–a practical solution to scaling up HCV therapy [Abstract 474]. Hepatology. 2018;68(suppl 1):283-284. doi:10.1002/hep.30257